R&D

R&D
GEXVal's Lead Program GXV-001 Receives FDA Rare Pediatric Disease DesignationNew!!

GEXVal Inc. November 18, 2026 GEXVal's Lead Program GXV-001 Receives Rare Pediatric Disease Designation from t […]

Read more
R&D
GEXVal Receives Funding from a Parkinson’s Research Program at The Michael J. Fox Foundation

GEXVal Inc.February 14, 2025 GEXVal Inc. (President & CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, […]

Read more
R&D
GEXVal Selected for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem’

GEXVal Inc.16 December, 2024 We are delighted to announce that GEXVal Inc.'s planned global Phase 2a Proof of […]

Read more
R&D
GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia

GEXVal Inc.July 1, 2024 GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia We are pleased to anno […]

Read more
R&D
GEXVal Sponsors SLTBR 2024 35th Annual Meeting

GEXVal Inc.June 18, 2024 GEXVal Sponsors SLTBR 2024 35th Annual Meeting GEXVal Inc. is proud to sponsor the 35 […]

Read more